Loading
The ESMO guideline for marginal zone lymphomas sets out the treatment of gastric and non-gastric extranodal, splenic and nodal forms, including antibiotic eradication, low-dose radiotherapy, watch and wait, rituximab-based therapy and BTK inhibitors at relapse.
Evidence-based guideline covering diagnosis, staging, and first-line and relapsed treatment of extranodal (MALT), splenic and nodal marginal zone lymphomas, including the role of infectious agents (Helicobacter pylori, hepatitis C), involved-site radiotherapy, chemoimmunotherapy and novel agents.
The site-specific and stage-specific approach on the marginal zone lymphoma page follows this guideline.
Shares Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma, Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma, Ocular adnexal MALT lymphoma, Gastric MALT lymphoma, Splenic marginal zone lymphoma.
Shares Ocular adnexal MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Splenic marginal zone lymphoma, Marginal zone lymphoma.
Shares Splenic marginal zone lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Ocular adnexal MALT lymphoma, Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.